•
Jul 02, 2023

Illumina Q2 2023 Earnings Report

Reported revenue increase of 1% year-over-year and 8% sequentially, with GAAP diluted loss per share of $(1.48) and non-GAAP diluted earnings per share of $0.32.

Key Takeaways

Illumina's Q2 2023 consolidated revenue reached $1.18 billion, a 1% increase year-over-year (3% on a constant currency basis) and an 8% increase sequentially from Q1 2023. The company shipped 109 NovaSeq X instruments. GAAP diluted loss per share was $(1.48), while non-GAAP diluted earnings per share was $0.32.

Revenue for Q2 2023 was $1.18 billion, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023

Shipped 109 NovaSeq X instruments in Q2 2023, boosting supply capacity to more than 390 instruments for fiscal year 2023

GAAP diluted loss per share of $(1.48) for Q2 2023, compared to GAAP diluted loss per share of $(3.40) for Q2 2022

Non-GAAP diluted earnings per share of $0.32 for Q2 2023, compared to non-GAAP diluted earnings per share of $0.57 for Q2 2022

Total Revenue
$1.18B
Previous year: $1.16B
+1.2%
EPS
$0.32
Previous year: $0.57
-43.9%
Gross Profit
$732M
Previous year: $802M
-8.7%
Cash and Equivalents
$1.55B
Previous year: $4.2B
-63.0%
Free Cash Flow
$58M
Previous year: $209M
-72.2%
Total Assets
$11.8B
Previous year: $8.68B
+35.7%

Illumina

Illumina

Forward Guidance

The company now expects fiscal year 2023 consolidated revenue growth of approximately 1% from 2022, including Core Illumina revenue that is approximately flat with 2022 and GRAIL revenue still in the range of $90 million to $110 million. The company now expects GAAP diluted loss per share of $(2.08) to $(1.93) and non-GAAP diluted earnings per share of $0.75 to $0.90.